Answers are grounded in this paper and cite their sources.
Metabolic-dysfunction-associated steatotic liver disease (MASLD) affects a substantial portion of US veterans and poses clinical and economic burdens. Blood-based noninvasive tests are recommended to stratify fibrosis and guide treatment decisions. However, the equity implications of alternative primary-care screening pathways remain unknown. This gap is especially salient in single-payer systems such as the US Veterans Health Administration (VHA), where resource allocation may involve trade-offs between maximizing total health and reducing disparities. We evaluated the efficiency and equity impact of a selected set of Fibrosis-4 Index (FIB-4)- and Enhanced Liver Fibrosis (ELF)-based screening strategies among US veterans. We conducted a distributional cost-effectiveness analysis (DCEA) from the VHA perspective comparing six screening strategies using the ELF and/or FIB-4 at varying cutoffs. Veterans were stratified into 15 subgroups by race/ethnicity and Social Vulnerability Index (SVI) quintiles. We adapted a previously published cost-effectiveness model, supplemented with subgroup-specific epidemiologic data and explicit distributional assumptions, to estimate subgroup-specific quality-adjusted life years (QALYs) and costs associated with screening and fibrosis treatment (resmetirom). Opportunity health effects were incorporated using a $100,000/QALY threshold (in 2026 US dollars). Health inequality was quantified using the Atkinson index. Compared with standard-of-care FIB-4 screening, sequential ELF screening at a 9.80 cutoff following indeterminate FIB-4 reduced referral and treatment intensity, resulting in direct health losses (91,370 QALYs) among screened veterans. However, the resulting cost savings generated opportunity health gains under the DCEA framework, yielding the largest net population health gains (185,010 QALYs) and the greatest reduction in health inequality (0.112%, or 194,690 equally distributed QALYs), assuming an Atkinson inequality aversion parameter of 12.2 and an opportunity-cost threshold of $100,000/QALY. In contrast, ELF 9.00 screening generated the largest direct QALY gains among screened veterans but was not preferred once opportunity health losses and distributional effects were incorporated. Results were generally consistent across sensitivity and scenario analyses, including scenarios with substantially reduced treatment costs, but were sensitive to assumptions regarding the extent to which cost savings were converted into opportunity health gains. Equity gains were greatest when cost savings were reinvested to improve health among more vulnerable groups. Among the FIB-4- and ELF-based screening strategies evaluated, sequential ELF screening at a 9.80 cutoff following FIB-4 generated the greatest net population health and equity gains under modeled assumptions and an opportunity-cost framework, despite reducing treatment intensity and direct health benefits among screened patients. These findings should be interpreted within the restricted comparator set, the assumptions governing subgroup differences, and the conversion of cost savings into health gains. More broadly, the analysis illustrates how incorporating equity considerations through DCEA can inform resource allocation within integrated health systems such as the VHA.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: